PMID: 2861973Mar 1, 1985

Biochemical and physiological effects of S-32-468, a beta-adrenoceptor antagonist with possible oculoselectivity

Current Eye Research
J A Nathanson

Abstract

S-32-468, a recently synthesized aryloxymethyl beta-adrenoceptor antagonist, was tested for its ability to inhibit activation of isoproterenol-stimulated adenylate cyclase activity in rabbit and human ciliary process, heart and lung. In both species, S-32-468 was a potent inhibitor of ocular beta-adrenoceptors, with a 9-12 fold selectivity over inhibition of beta-adrenoceptors in cardiac tissue. When applied topically, S-32-468 was more effective than timolol in decreasing intraocular pressure in normal albino rabbits.

References

Jul 1, 1977·British Journal of Pharmacology·J L ImbsC G Wermuth
May 1, 1981·British Journal of Pharmacology·J A Nathanson
Aug 1, 1983·The British Journal of Ophthalmology·A Rushton
Jan 1, 1984·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·C J SchmittN N Share
Dec 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·J A Nathanson
Dec 1, 1982·The British Journal of Ophthalmology·G E Trope, B Clark

Citations

Nov 1, 1988·The Journal of Pharmacy and Pharmacology·J A Nathanson, E J Hunnicutt

Related Concepts

4-(3-tert-butylamino-2-hydroxypropoxy)spiro(cyclohexane-1,2-indan)-1-one
Adenylate Cyclase
Adrenergic beta-Antagonists
Ciliary Body
Enzyme Activation
Physiologic Intraocular Pressure
Novodrin
Lung
Myocardium
Propanolamines

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.